Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Pyxis Oncology, Inc. has received an average rating of "Moderate Buy" from seven analysts, with one sell rating, one hold, four buys, and one strong buy.
• The average 12-month price target set by brokerages for Pyxis Oncology is $7.75.
• Recent activities by institutional investors have increased their ownership in Pyxis Oncology, which is currently at 39.09%.

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $7.75.

PYXS has been the topic of a number of analyst reports. Zacks Research raised shares of Pyxis Oncology from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 13th. Wall Street Zen lowered shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research report on Friday, October 3rd. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Guggenheim began coverage on shares of Pyxis Oncology in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $5.00 price target on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PYXS. Jane Street Group LLC acquired a new position in Pyxis Oncology in the second quarter valued at about $370,000. Pier 88 Investment Partners LLC lifted its position in shares of Pyxis Oncology by 296.6% during the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after purchasing an additional 292,370 shares in the last quarter. Schulhoff & Co. Inc. lifted its position in shares of Pyxis Oncology by 125.4% during the second quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company's stock worth $302,000 after purchasing an additional 153,000 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Pyxis Oncology during the second quarter worth approximately $163,000. Finally, 683 Capital Management LLC lifted its position in shares of Pyxis Oncology by 32.5% during the first quarter. 683 Capital Management LLC now owns 550,000 shares of the company's stock worth $539,000 after purchasing an additional 135,000 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Up 0.3%

NASDAQ PYXS opened at $3.36 on Friday. The stock has a market cap of $208.39 million, a P/E ratio of -2.10 and a beta of 1.33. The company's 50-day simple moving average is $2.02 and its 200 day simple moving average is $1.44. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The business had revenue of $2.82 million during the quarter. Research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.